4,709 Shares of Danaher Corporation $DHR Acquired by Whalen Wealth Management Inc.

Whalen Wealth Management Inc. acquired a new position in shares of Danaher Corporation (NYSE:DHR) during the third quarter, HoldingsChannel reports. The fund acquired 4,709 shares of the conglomerate’s stock, valued at approximately $1,043,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. EP Wealth Advisors LLC acquired a new position in shares of Danaher in the 2nd quarter valued at $3,807,000. Puzo Michael J acquired a new stake in shares of Danaher during the 2nd quarter valued at about $8,624,000. Madison Asset Management LLC acquired a new stake in shares of Danaher during the 2nd quarter valued at about $85,451,000. First Nebraska Trust Co bought a new stake in Danaher in the second quarter valued at about $14,106,000. Finally, Colton Groome Financial Advisors LLC acquired a new position in Danaher in the third quarter worth about $592,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of NYSE DHR traded down $4.16 during mid-day trading on Thursday, hitting $214.33. 2,379,154 shares of the stock were exchanged, compared to its average volume of 4,448,717. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The stock’s fifty day simple moving average is $210.46 and its two-hundred day simple moving average is $194.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company has a market cap of $150.67 billion, a P/E ratio of 38.05, a PEG ratio of 2.68 and a beta of 0.76.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.Danaher’s revenue was up 5.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.77 EPS. As a group, analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 28.42%.

Wall Street Analyst Weigh In

A number of research analysts have commented on DHR shares. Royal Bank Of Canada raised their price target on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday. Piper Sandler assumed coverage on Danaher in a report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 target price for the company. Wells Fargo & Company decreased their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 22nd. Barclays upped their price target on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, UBS Group initiated coverage on Danaher in a report on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $235.23.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.